The Gladstone Institute of Data Science & Biotechnology, San Francisco, California, USA.
Department of Pathology and Geriatrics Center, University of Michigan, Ann Arbor, Michigan, USA.
mSphere. 2021 Dec 22;6(6):e0085121. doi: 10.1128/msphere.00851-21. Epub 2021 Dec 1.
The drug acarbose is used to treat diabetes and, by inhibiting α-amylase in the small intestine, increases the amount of starch entering the lower digestive tract. This results in changes to the composition of the microbiota and their fermentation products. Acarbose also increases longevity in mice, an effect that has been correlated with increased production of the short-chain fatty acids propionate and butyrate. In experiments replicated across three study sites, two distantly related species in the bacterial family were dramatically more abundant in acarbose-treated mice, distinguishing these responders from other members of the family. Bacteria in the family are predicted to produce propionate as a fermentation end product and are abundant and diverse in the guts of mice, although few isolates are available. We reconstructed genomes from metagenomes (MAGs) for nine populations of to examine factors that distinguish species that respond positively to acarbose. We found two closely related MAGs (B1A and B1B) from one responsive species that both contain a polysaccharide utilization locus with a predicted extracellular α-amylase. These genomes also shared a periplasmic neopullulanase with another, distantly related MAG (B2) representative of the only other responsive species. This gene differentiated these three MAGs from MAGs representative of nonresponding species. Differential gene content in B1A and B1B may be associated with the inconsistent response of this species to acarbose across study sites. This work demonstrates the utility of culture-free genomics for inferring the ecological roles of gut bacteria, including their response to pharmaceutical perturbations. The drug acarbose is used to treat diabetes by preventing the breakdown of starch in the small intestine, resulting in dramatic changes in the abundance of some members of the gut microbiome and its fermentation products. In mice, several of the bacteria that respond most positively are classified in the family , members of which produce propionate as a primary fermentation product. Propionate has been associated with gut health and increased longevity in mice. We found that genomes of the most responsive showed signs of specialization for starch fermentation, presumably providing them a competitive advantage in the large intestine of animals consuming acarbose. Comparisons among genomes enhance existing models for the ecological niches occupied by members of this family. In addition, genes encoding one type of enzyme known to participate in starch breakdown were found in all three genomes from responding species but none of the other genomes.
阿卡波糖用于治疗糖尿病,通过抑制小肠中的α-淀粉酶,增加进入下消化道的淀粉量。这导致微生物群及其发酵产物的组成发生变化。阿卡波糖还能延长小鼠的寿命,这种效果与短链脂肪酸丙酸和丁酸产量的增加有关。在三个研究地点重复的实验中,两种远缘细菌家族的细菌在接受阿卡波糖治疗的小鼠中明显更为丰富,这将这些应答者与家族中的其他成员区分开来。细菌家族被预测会产生丙酸作为发酵的终产物,并且在小鼠的肠道中丰富多样,尽管可用的分离株很少。我们从宏基因组(MAGs)重建了 九个种群的基因组,以研究区分对阿卡波糖产生积极反应的物种的因素。我们从一种应答物种中发现了两个密切相关的 MAG(B1A 和 B1B),它们都含有一个预测的细胞外α-淀粉酶多糖利用基因座。这些基因组还与另一个远缘 MAG(B2)共享一个周质新普鲁兰酶,该 MAG 代表唯一另一种应答物种。这个基因将这三个 MAG 与代表非应答物种的 MAG 区分开来。B1A 和 B1B 中的差异基因表达可能与该物种在不同研究地点对阿卡波糖的不一致反应有关。这项工作证明了无培养基因组学在推断肠道细菌的生态作用方面的效用,包括它们对药物干扰的反应。阿卡波糖用于治疗糖尿病,通过防止小肠中淀粉的分解,导致肠道微生物组的一些成员及其发酵产物的丰度发生显著变化。在小鼠中,对药物反应最积极的几种细菌被分类为 家族,该家族的成员将丙酸作为主要发酵产物。丙酸与肠道健康和小鼠寿命延长有关。我们发现,响应最强烈的 基因组显示出对淀粉发酵的专门化迹象,这可能使它们在食用阿卡波糖的动物的大肠中具有竞争优势。对基因组的比较增强了该家族成员所占据的生态位的现有模型。此外,在所有三种来自应答物种的基因组中都发现了编码一种已知参与淀粉分解的酶的基因,但在其他所有基因组中都没有发现。
Appl Environ Microbiol. 2021-7-27
J Nutr. 1997-5
Microbiol Spectr. 2022-8-31
BMJ Open Diabetes Res Care. 2019-9-20
J Orthop Surg Res. 2025-8-30
Commun Biol. 2025-3-8